The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pseudo-What? Exploring the Classification Criteria Development Process for CPPD

Pseudo-What? Exploring the Classification Criteria Development Process for CPPD

December 12, 2022 • By Jason Liebowitz, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

PHILADELPHIA—The term pseudogout has been a source of confusion among rheumatologists, especially as our understanding of calcium pyrophosphate crystal deposition (CPPD) disease has become more nuanced. This condition has many complex and interesting facets that warrant closer investigation.

You Might Also Like
  • New Study Works Toward Better Lupus Classification Criteria
  • Draft Classification Criteria for IgG4-Related Disease Introduced
  • The ACR, EULAR Partner to Refine Classification System, Develop New SLE Criteria
Also By This Author
  • A Primer on the Management of Scleroderma Emergencies

An ACR Convergence 2022 session sought to update the audience on the progress to date in developing classification criteria for CPPD disease. The first speaker was Sara Tedeschi, MD, MPH, assistant professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital, Boston. She discussed the methodology and item considerations in developing the new classification criteria.1

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Tedeschi noted that CPPD disease is common, but research on the condition has been stymied by the lack of validated classification criteria, reliance on synovial fluid polarized light microscopy for diagnosis and the disease’s diversity of presentations. These presentations can include acute CPP crystal arthritis (i.e., the condition historically called pseudogout), chronic CPP crystal inflammatory arthritis, osteoarthritis with CPPD and crowned dens syndromes.

Developing Classification Criteria

Using a four-phase process that began in 2019, the group working on the classification criteria used data and expert opinion from rheumatologists, a musculoskeletal radiologist and a methodologist from across the country and world to advance the project.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The first phase of the process was item generation, which included a literature review and the solicitation of suggestions from patients and a combined expert committee. The second phase was item reduction and refinement, which included discussions with an advisory group focused on clinical, laboratory and imaging data, as well as an item rating exercise by combined expert committee members. Here, Dr. Tedeschi referenced a paper she wrote with colleagues in which imaging features characteristic of CPPD on radiographs, computed tomography (CT) scans and dual-energy CT (DECT) studies were defined and a set of example images was compiled.2

In the study’s third phase, item weighting and threshold scoring was pursued. The group assembled a derivation cohort, which refers to a group of patients who would be used for testing some of the features of the classification criteria framework. Rheumatologists from 13 sites and six countries provided data from de-identified patients and were asked to rate their clinical suspicion for CPPD disease on a scale of -3 (least likely) to +3 (most likely).

Next, two blinded expert adjudicators from different institutions reviewed each case. The group then used data from the adjudicators, the rheumatologists who submitted the cases and information from synovial fluid analysis (when present) to define three patient categories: definite cases, definite mimickers (who then served as the control group) and uncertain. The group identified features of clinical cases that increased the odds ratio (OR) of a patient’s likelihood of having CPPD disease, such as if the patient ever had an acute inflammatory arthritis of the knee (OR 3.0, 95%; confidence interval [CI] 1.9–4.8) or the patient having more than one typical episode of acute inflammatory arthritis (OR 4.1, 95%; CI 2.5–6.7).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Conditions, Crystal Arthritis, Meeting Reports Tagged With: ACR Convergence 2022, ACR Convergence 2022 – Gout, Gout

You Might Also Like:
  • New Study Works Toward Better Lupus Classification Criteria
  • Draft Classification Criteria for IgG4-Related Disease Introduced
  • The ACR, EULAR Partner to Refine Classification System, Develop New SLE Criteria
  • New SLE Criteria Under Development: A Joint Effort of the ACR & EULAR

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)